MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Clin Cancer Res
; 23(17): 5218-5224, 2017 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-28533223
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzimidazoles
/
Breast Neoplasms
/
Cyclin-Dependent Kinase 4
/
Cyclin-Dependent Kinase 6
/
Aminopyridines
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2017
Document type:
Article
Country of publication:
United States